zasocitinib
takeda
['ndi-034858', 'psoriasis', 'tak-279', 'takeda', 'nimbus']
results from the phase 2b clinical trial of tak-279 (formerly ndi-034858), a novel allosteric tyk2 inhibitor developed by nimbus and owned by takeda, in patients with moderate-to-severe plaque psoriasis were presented at the 2023 annual meeting: 
We integrate computational chemistry and other advanced technologies to design breakthrough medicines and transform drug development. https://t.co/gANxj1Ufzq